Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Akebia Therapeutics Inc is a biotechnology business based in the US. Akebia Therapeutics shares (AKBA) are listed on the NASDAQ and all prices are listed in US Dollars. Akebia Therapeutics employs 379 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.85|
|52-week range||$2.09 - $5.14|
|50-day moving average||$2.89|
|200-day moving average||$3.09|
|Wall St. target price||$6.54|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.99|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-07)||1.79%|
|1 month (2021-09-17)||-1.72%|
|3 months (2021-07-17)||-16.42%|
|6 months (2021-04-16)||-3.72%|
|1 year (2020-10-16)||-24.60%|
|2 years (2019-10-17)||-33.72%|
|3 years (2018-10-17)||8.91|
|5 years (2016-10-17)||7.96|
|Revenue TTM||$221.9 million|
|Gross profit TTM||$12.9 million|
|Return on assets TTM||-20.18%|
|Return on equity TTM||-109.96%|
|Market capitalisation||$497.4 million|
TTM: trailing 12 months
There are currently 12.7 million Akebia Therapeutics shares held short by investors – that's known as Akebia Therapeutics's "short interest". This figure is 1.5% up from 12.5 million last month.
There are a few different ways that this level of interest in shorting Akebia Therapeutics shares can be evaluated.
Akebia Therapeutics's "short interest ratio" (SIR) is the quantity of Akebia Therapeutics shares currently shorted divided by the average quantity of Akebia Therapeutics shares traded daily (recently around 2.0 million). Akebia Therapeutics's SIR currently stands at 6.42. In other words for every 100,000 Akebia Therapeutics shares traded daily on the market, roughly 6420 shares are currently held short.
However Akebia Therapeutics's short interest can also be evaluated against the total number of Akebia Therapeutics shares, or, against the total number of tradable Akebia Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akebia Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Akebia Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.0734% of the tradable shares (for every 100,000 tradable Akebia Therapeutics shares, roughly 73 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Akebia Therapeutics.
Find out more about how you can short Akebia Therapeutics stock.
We're not expecting Akebia Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Akebia Therapeutics's shares have ranged in value from as little as $2.09 up to $5.14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akebia Therapeutics's is 1.6693. This would suggest that Akebia Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Akebia Therapeutics, Inc. , a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.